Intervacc ABFRA:2E9 +0.45%62 Gross Margin % is 31.63% as of Mar. 2026, which is 17% above its 10-year median of 27.12. GuruFocus rates FRA:2E9 with a GF Score™ of 62/100 and a GF Value™ of €0.06. The stock has 5 warning signs investors should review. Among 733 Biotechnology companies, Intervacc AB ranks worse than 95.5% on this metric.
The historical rank and industry rank for Intervacc AB's Gross Margin % or its related term are showing as below:
FRA:2E9'
s Gross Margin % Range Over the Past 10 Years
Min: -172.1 Med: 27.12 Max: 119.18
Current: -67.82
During the past 12 years, the highestGross Margin % of Intervacc AB was 119.18%. The lowest was -172.10%. And the median was 27.12%.
FRA:2E9's Gross Margin % is ranked worse than 95.5% of 733
companies
in the Biotechnology industry
Industry Median: 60.9
vs FRA:2E9: -67.82
Intervacc AB had a gross margin of 31.63% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Intervacc AB was 0.00% per year.
Intervacc AB (FRA:2E9) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Intervacc AB had a gross margin of 31.63% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Intervacc AB Gross Margin % Related Terms
Intervacc AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Intervacc AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E9 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Intervacc AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Intervacc AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Intervacc AB (FRA:2E9) has a Gross Margin % of 31.63% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Intervacc AB and its competitors. This is 17% above median its historical median of 27.12. According to the industry distribution chart, Intervacc AB ranks #700 out of 733 companies in the Biotechnology industry, placing it in the top 95.5%.
Is Intervacc AB's Gross Margin % too high?
Intervacc AB's current Gross Margin % of 31.63% is 17% above median its 10-year median of 27.12. The Biotechnology industry median Gross Margin % is 60.90. Intervacc AB's value of 31.63% is 48.1% below this industry median. Based on the distribution chart, Intervacc AB ranks #700 out of 733 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Intervacc AB has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #700 out of 733 companies for Gross Margin %. This places Intervacc AB in the lower half of its industry. The industry median Gross Margin % is 60.90. Intervacc AB's value of 31.63% is 48.1% below this benchmark. While the company's 10-year median is 27.12 vs. the industry median of 60.90, Intervacc AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intervacc AB's current Gross Margin % of 31.63% is 48.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Intervacc AB and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intervacc AB's current Gross Margin % is 31.63%, which is 17% above median its own 10-year median of 27.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Gross Margin % of 31.63%. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 12.5% above its estimated fair value. The current Gross Margin % is 31.63%, which is 17% above median its 10-year median of 27.12 and 48.1% below the Biotechnology industry median of 60.90. Intervacc AB's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Gross Margin % is 31.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued.
The current stock price of €0.07 is trading 12.5% above its estimated GF Value™ of €0.06.
Key valuation signals for FRA:2E9:
Gross Margin %: 31.63% (17% above median its 10-year median of 27.12)
GF Value™: €0.06 vs. price of €0.07 (12.5% above fair value)
Industry Position: 48.1% below the Biotechnology median (#700 of 733)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
62GF Score
Get the complete analysis for FRA:2E9
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
